安科生物：参股公司PA3-17注射液获准进入关键性II期临床试验

Core Viewpoint - The announcement highlights that the affiliated companies of Anke Bio, Boshengji Pharmaceutical Technology (Suzhou) Co., Ltd. and Boshengji Anke Cell Technology Co., Ltd., have received approval from the National Medical Products Administration (NMPA) for the key Phase II clinical trial of PA3-17 injection, a targeted CAR-T cell therapy product for treating adult relapsed and refractory CD7-positive hematological malignancies [1]. Group 1 - The PA3-17 injection is the world's first CAR-T cell therapy product targeting CD7 that has received clinical trial approval [1]. - The approval allows the applicant to proceed with critical Phase II clinical trials [1]. - The product is specifically designed for adult patients with relapsed and refractory CD7-positive hematological malignancies [1].